Loading clinical trials...

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study | Clinical Trials | Clareo Health

TERMINATED

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study

A Multicenter, Observational, 6-Month Follow-up Study of Patients With COVID-19 Previously Enrolled in a RO7496998 (AT-527) Study

NCT05059080•Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 \[CV43043\]), for approximately 6 months after the end of the parent study.

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participant was diagnosed with COVID-19 and enrolled in a Phase III RO7496998 (AT-527) COVID-19 study

Exclusion Criteria

•Participation in an interventional study at the time of enrollment or plans to enroll in an interventional study during this study.
•Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

Locations (35)

Instituto Ave Pulmo

Mar del Plata, Argentina

Private Practice Dr Jean Benoit Martinot

Erpent, Belgium

Medif

Gozée, Belgium

L2IP -Instituto de Pesquisas Clínicas Ltda.

Brasília, Federal District, Brazil

Chronos Pesquisa Clinica

Taguatinga, Federal District, Brazil

Hospital Nossa Senhora das Graças

Curitiba, Paraná, Brazil

Hospital Agamenon Magalhães

Recife, Pernambuco, Brazil

Conjunto Hospitalar do Mandaqui

São Paulo, São Paulo, Brazil

Aalborg Universitetshospital

Aalborg, Denmark

Rigshospitalet Copenhagen University Hospital

Copenhagen, Denmark

Key Dates

Start Date

June 15, 2021

Primary Completion Date

March 7, 2022

Completion Date

March 16, 2022

Last Updated

July 28, 2023

Enrollment

ACTUAL participants

Conditions

COVID-19Long COVID

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITINGPHASE2/PHASE3

Taurine Supplementation in Long COVID

NCT06721949

Long COVID

View study

RECRUITINGPHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study

Inclusion Criteria

Exclusion Criteria

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Taurine Supplementation in Long COVID

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate